Trial · NCT00832871
Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers
NCT00832871, Not applicable, Terminated, New Mexico Cancer Research Alliance; results first posted 2016-08-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers. Trials, record NCT00832871. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00832871
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers
- NCT number
- NCT00832871
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 4 participants, actual
- Lead sponsor
- New Mexico Cancer Research Alliance
- Conditions
- Cancer
- Interventions
- Mifepristone
- First posted
- 2009-01-30
- Last updated
- 2018-06-29
- Results first posted
- 2016-08-02
- Limitations and caveats
This is a compassionate use protocol. No statistical analysis was specified in the protocol; it states that only descriptive data will be collected. Data from only 4 patients should not be considered reliable.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of Response | 5 years | The time from the date of response (not the beginning of treatment unless there is stable disease) to disease progression. Response and progression are evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Target lesions are assessed by computerized tomography (CT) or magnetic resonance imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient decrease in the sum of the longest diameter of target lesions to qualify for PR nor sufficient increase in the sum of the longest diameter of target lesions to qualify for Progressive Disease; Progressive Disease (PD), 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
| Secondary | Toxicity Associated With Adrenal Insufficiency | Up to 8 weeks after the end of study treatment or until any adverse events are resolved (whichever is longest) | Toxicity will be evaluated per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Frequency and severity of adverse events will be tabulated using counts the following events of interest, which are related to possible adrenal insufficiency: nausea, vomiting, lethargy, dizziness, fatigue, anorexia, and skin rash. Any grade of these events that are self-reported by patients as well as events identified by physician assessment (e.g. physical exam) will be included. |
| Other | Overall Survival | 5 years | The time from patient entry into the protocol to death by any cause. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Duration of Response | 5 years | Only one patient achieved stable disease. This patient's duration of response could therefore be reported. The other three patients progressed on treatment. | days | MEDIAN |
| SECONDARY | Toxicity Associated With Adrenal Insufficiency | Up to 8 weeks after the end of study treatment or until any adverse events are resolved (whichever is longest) | All patients received at least one dose of study medication and are included in this analysis. | percentage of participants | NUMBER |
| OTHER_PRE_SPECIFIED | Overall Survival | 5 years | Months | MEDIAN |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Response | Mifepristone | 44 | Full Range 44 to 44 | days | |
| Toxicity Associated With Adrenal Insufficiency | Mifepristone | Nausea | 0 | percentage of participants | |
| Toxicity Associated With Adrenal Insufficiency | Mifepristone | Vomiting | 0 | percentage of participants | |
| Toxicity Associated With Adrenal Insufficiency | Mifepristone | Lethargy | 0 | percentage of participants | |
| Toxicity Associated With Adrenal Insufficiency | Mifepristone | Dizziness | 0 | percentage of participants | |
| Toxicity Associated With Adrenal Insufficiency | Mifepristone | Fatigue | 0 | percentage of participants | |
| Toxicity Associated With Adrenal Insufficiency | Mifepristone | Anorexia | 0 | percentage of participants | |
| Toxicity Associated With Adrenal Insufficiency | Mifepristone | Skin Rash | 0 | percentage of participants | |
| Overall Survival | Mifepristone | 24.2 | Standard Deviation 28.5 | Months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mifepristone | 4 | |
| Overall Study | COMPLETED | Mifepristone | 4 | |
| Overall Study | NOT COMPLETED | Mifepristone | 0 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Edema: limb | Blood and lymphatic system disorders | Mifepristone | 1 | 4 | 1 |
| other | Edema: trunk | Blood and lymphatic system disorders | Mifepristone | 1 | 4 | 1 |
| other | Headache | Nervous system disorders | Mifepristone | 1 | 4 | 1 |
| other | Watery eye | Eye disorders | Mifepristone | 1 | 4 | 1 |
| other | Diplopia | Eye disorders | Mifepristone | 1 | 4 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mifepristone | ||
| Total, other adverse events | Mifepristone | 2 | 4 |
| Total, serious adverse events | Mifepristone | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00832871
GET https://conductscience.org/api/trials/v1/NCT00832871/registered